| 1 |
To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified. |
|
| 1a |
Jacqueline K. Barton, Ph.D. |
✓ For(116.7)
|
| 1b |
Jeffrey A. Bluestone, Ph.D. |
✓ For(116.7)
|
| 1c |
Sandra J. Horning, M.D. |
✓ For(116.7)
|
| 1d |
Kelly A. Kramer |
✓ For(116.7)
|
| 1e |
Ted W. Love, M.D. |
✓ For(116.7)
|
| 1f |
Harish Manwani |
✓ For(116.7)
|
| 1g |
Daniel P. O'Day |
✗ Against(116.7)
|
| 1h |
Javier J. Rodriguez |
✓ For(116.7)
|
| 1i |
Anthony Welters |
✓ For(116.7)
|
| 2 |
To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026. |
✓ For(116.7)
|
| 3 |
To approve, on an advisory basis, the compensation of our Named Executive Officers as presented in the Proxy Statement. |
✓ For(116.7)
|
| 4 |
To approve the amended and restated Gilead Sciences, Inc. 2022 Equity Incentive Plan. |
✓ For(116.7)
|
| 5 |
To vote on a stockholder proposal requesting an independent Board Chair policy, if properly presented at the Annual Meeting. |
✗ Against(116.7)
|
| 6 |
To vote on a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access, if properly presented at the Annual Meeting. |
✗ Against(116.7)
|
| 7 |
To vote on a stockholder proposal requesting a report on the risks of ESG and DEI executive compensation metrics, if properly presented at the Annual Meeting. |
✗ Against(116.7)
|
rebel Financial